ACRV ▲ +3.6% - Acrivon Therapeutics, Inc. $ACRV - Acrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 2027 20-OCT-2026 08:30 AM ET